Shares of Dynavax Technologies Corporation (NASDAQ:DVAX) have earned an average rating of “Buy” from the eight research firms that are currently covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $27.40.

A number of equities research analysts have issued reports on DVAX shares. Royal Bank Of Canada reiterated a “buy” rating and issued a $26.00 target price on shares of Dynavax Technologies Corporation in a research report on Friday, September 1st. Cowen and Company reiterated an “outperform” rating and issued a $45.00 target price on shares of Dynavax Technologies Corporation in a research report on Thursday, July 27th. William Blair reiterated an “outperform” rating on shares of Dynavax Technologies Corporation in a research report on Thursday, July 27th. Cantor Fitzgerald started coverage on shares of Dynavax Technologies Corporation in a research report on Friday. They issued an “overweight” rating and a $24.00 target price for the company. Finally, ValuEngine downgraded shares of Dynavax Technologies Corporation from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd.

Shares of Dynavax Technologies Corporation (NASDAQ:DVAX) opened at 20.75 on Tuesday. The stock’s 50 day moving average is $17.69 and its 200 day moving average is $9.68. Dynavax Technologies Corporation has a 52 week low of $3.20 and a 52 week high of $21.85. The stock’s market capitalization is $1.14 billion.

Dynavax Technologies Corporation (NASDAQ:DVAX) last released its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.09. Dynavax Technologies Corporation had a negative net margin of 1,323.99% and a negative return on equity of 92.09%. The company had revenue of $0.11 million during the quarter, compared to the consensus estimate of $0.15 million. During the same quarter in the prior year, the firm earned ($0.75) EPS. Analysts anticipate that Dynavax Technologies Corporation will post ($1.60) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Dynavax Technologies Corporation (DVAX) Given Average Rating of “Buy” by Brokerages” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/09/19/dynavax-technologies-corporation-dvax-given-average-rating-of-buy-by-brokerages.html.

Several institutional investors and hedge funds have recently made changes to their positions in DVAX. Teachers Advisors LLC increased its stake in shares of Dynavax Technologies Corporation by 9.1% during the 4th quarter. Teachers Advisors LLC now owns 67,640 shares of the biopharmaceutical company’s stock worth $267,000 after purchasing an additional 5,618 shares during the last quarter. Nationwide Fund Advisors increased its stake in shares of Dynavax Technologies Corporation by 11.2% during the 1st quarter. Nationwide Fund Advisors now owns 27,667 shares of the biopharmaceutical company’s stock worth $165,000 after purchasing an additional 2,786 shares during the last quarter. Russell Investments Group Ltd. increased its stake in shares of Dynavax Technologies Corporation by 61.7% during the 1st quarter. Russell Investments Group Ltd. now owns 125,059 shares of the biopharmaceutical company’s stock worth $744,000 after purchasing an additional 47,735 shares during the last quarter. Wells Fargo & Company MN increased its stake in shares of Dynavax Technologies Corporation by 30.0% during the 1st quarter. Wells Fargo & Company MN now owns 41,743 shares of the biopharmaceutical company’s stock worth $248,000 after purchasing an additional 9,634 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale acquired a new position in shares of Dynavax Technologies Corporation during the 1st quarter worth $121,000. Institutional investors own 60.20% of the company’s stock.

Dynavax Technologies Corporation Company Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Analyst Recommendations for Dynavax Technologies Corporation (NASDAQ:DVAX)

Receive News & Stock Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related stocks with our FREE daily email newsletter.